Schiff Advises Moleculin Biotech, Inc. on its $78M Public Offering

News

Schiff Advises Moleculin Biotech, Inc. on its $78M Public Offering

News Release |

Schiff Hardin LLP advised Moleculin Biotech, Inc. in connection with its public offering of 16,414,736 shares of common stock for gross proceeds of approximately $78 million. Moleculin is a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses. The offering closed February 10, 2021.